LAVA Therapeutics NV (LVTX)
3.05
-0.05
(-1.61%)
USD |
NASDAQ |
May 03, 16:00
3.05
0.00 (0.00%)
After-Hours: 20:00
LAVA Therapeutics Debt to Equity Ratio: 0.1032 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.1032 |
| September 30, 2023 | 0.0906 |
| June 30, 2023 | 0.0775 |
| March 31, 2023 | 0.0645 |
| December 31, 2022 | 0.0539 |
| September 30, 2022 | 0.045 |
| June 30, 2022 | 0.046 |
| Date | Value |
|---|---|
| March 31, 2022 | 0.0416 |
| December 31, 2021 | 0.0362 |
| September 30, 2021 | 0.0318 |
| June 30, 2021 | 0.0282 |
| March 31, 2021 | 0.0265 |
| December 31, 2020 | 0.4729 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.0265
Minimum
Mar 2021
0.4729
Maximum
Dec 2020
0.086
Average
0.046
Median
Jun 2022
Debt to Equity Ratio Benchmarks
| uniQure NV | 0.49 |
| ProQR Therapeutics NV | 0.1037 |
| Merus NV | 0.00 |
| argenx SE | 0.00 |
| Pharming Group | 0.6327 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 101.71M |
| Total Liabilities (Quarterly) | 50.53M |
| Shareholders Equity (Quarterly) | 51.18M |
| Current Ratio | 6.619 |
| Net Debt Paydown Yield | -0.53% |